Telomir Pharmaceuticals, Inc. - Common Stock (TELO)

Telomir-1 shows potential in oncology and age-related diseases, with new findings on its role in tumor suppression and chemotherapy toxicity reduction.

Telomir Pharmaceuticals' Telomir-1 stabilizes Silver(II) for medical use, addressing instability issues in antimicrobial treatments and wound care solutions.

Telomir-1 shows potential as a treatment for Wilson's disease and related disorders, with promising preclinical results and potential for orphan drug designation.

Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation

Telomir Pharmaceuticals unveils preclinical data on Telomir-1, highlighting its potential in Type 2 diabetes, aging, and inflammatory diseases.

Turning Back The Clock On Aging: Telomir Pharmaceuticals Confirms Telomir-1 Reverses Age And Increased Longevity In Breakthrough Pre-Clinical Study

Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs

Telomir Pharmaceuticals just reported results for the second quarter of 2024.

From Pets To Humans, Telomir Pharmaceuticals (NASDAQ: TELO) Holds The Key To Extending Life, Reversing Aging

Telomir Pharmaceuticals just reported results for the first quarter of 2024.

Shares of AppLovin Corporation (NASDAQ: APP) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial

Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings.

U.S. stock futures were higher this morning, with the Dow futures trading higher by around 70 points on Thursday.

Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a drug developer this year.